Search

Your search keyword '"Sharman, David"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Sharman, David" Remove constraint Author: "Sharman, David"
46 results on '"Sharman, David"'

Search Results

1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

4. Strategies to improve atrioventricular synchrony in patients with a Micra AV leadless pacemaker.

5. A leadless pacemaker in the real‐world setting: Patient profile and performance over time

10. Contribution of NOTCH1 genetic variants to bicuspid aortic valve and other congenital lesions

13. Dumbleton march on in bid to repeat 2022 Lord's win.

14. All's fair as Scarborough chase national double.

15. Reed's revive dying art of declarations.

16. Shocks guarantee fresh faces for Lord's final.

17. From the Cradle of Cricket to the Home of Cricket.

20. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

21. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

22. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

23. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

25. Optical character recognition for self-service banking

26. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

27. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

30. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

33. Valuing architecture for strategic purposes : comments on applying the dependency structure matrix with real options theory

40. Characterizing complex product architectures

42. Why I selected this piece.

45. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

46. Strategies to improve atrioventricular synchrony in patients with a Micra AV leadless pacemaker.

Catalog

Books, media, physical & digital resources